Cartesian Reports Positive Phase 2 Retreatment Data For Descartes-08
Cartesian Therapeutics (RNAC) reported Phase 2 retreatment data for Descartes-08 in generalized myasthenia gravis, showing sustained symptom improvements 12 months post-retreatment. The study involved five patients, with mean MG-ADL and MGC scores decreasing by 6.6 and 15 points, respectively. The company plans to report Phase 3 results in Q1 2027 and submit a BLA in mid-2027. RNAC stock closed at $7.21, down 2.70%.
How this was made
The 30-second read
Why it matters
The retreatment data provide the first evidence of durable efficacy after re‑dosing, supporting the upcoming Phase 3 AURORA trial and BLA filing timeline.
Market read
Positive retreatment data could lift RNAC ahead of its Phase 3 readout, influencing biotech sector sentiment.
What to watch
Potential manufacturing or regulatory hurdles could temper upside despite positive data.
Background
Cartesian Therapeutics is developing Descartes-08, an autologous CAR‑T therapy targeting BCMA for myasthenia gravis and myositis.
Ticker impact
Cartesian Therapeutics disclosed new Phase 2 retreatment data for Descartes-08 showing sustained symptom improvement in myasthenia gravis patients.
upward pressure as investors price in favorable trial data
The data are the first public disclosure of retreatment efficacy, a material catalyst for a biotech with an upcoming Phase 3 readout.
Market effects
May boost sentiment for CAR‑T and autoimmune therapy peers.
Limited to US biotech sector.
Modest, primarily affects investors tracking biotech pipelines.
Counterpoint
Skeptics may question the small sample size (5 patients) and await Phase 3 confirmation.
Key entities
- companyCartesian Therapeutics
Biotech firm developing Descartes-08 CAR‑T therapy.
- productDescartes-08
Investigational autologous CAR‑T therapy targeting BCMA.
